CSIMarket Company Name, Ticker, Suppliers, else..
 
Werewolf Therapeutics Inc   (NASDAQ: HOWL)
Other Ticker:  
 
 
Price: $0.8544 $-0.02 -2.265%
Day's High: $0.908 Week Perf: 10.7 %
Day's Low: $ 0.83 30 Day Perf: -21.61 %
Volume (M): 158 52 Wk High: $ 6.89
Volume (M$): $ 135 52 Wk Avg: $2.29
Open: $0.90 52 Wk Low: $0.60



 Market Capitalization (Millions $) 37
 Shares Outstanding (Millions) 43
 Employees 18
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -71
 Cash Flow (TTM) (Millions $) -43
 Capital Exp. (TTM) (Millions $) 0

Werewolf Therapeutics Inc
Werewolf Therapeutics Inc is a biotechnology company focused on developing novel cancer therapeutics. The company's approach involves utilizing the body's immune system to target and eliminate cancer cells. Werewolf Therapeutics aims to create innovative therapies that can improve patient outcomes and address the limitations of current cancer treatments. They use a unique platform technology called the Werewolf Oncolytic Virus to develop their drug candidates, which are designed to selectively attack and destroy cancer cells while sparing healthy cells. The company is committed to advancing groundbreaking therapies that have the potential to transform the field of cancer treatment.


   Company Address: 200 Talcott Ave Watertown 2472 MA
   Company Phone Number: 952?0555   Stock Exchange / Ticker: NASDAQ HOWL


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY      % 
HCM        9.63% 
LLY        9.63% 
PFE        9.63% 
REGN        6.13% 
SNY        6.13% 
• View Complete Report
   



Clinical Study

Breakthrough in Cancer Immunotherapy Werewolf Therapeutics Reports Promising Phase 1 Clinical Data for Tumor-Act...

Published Thu, Nov 7 2024 2:02 PM UTC

Werewolf Therapeutics Showcases Promising Data for WTX-330 at SITC Annual MeetingIn a significant contribution to cancer immunotherapy, Werewolf Therapeutics has presented both preclinical and clinical data on its investigational tumor-activated interleukin-12 (IL-12) prodrug, WTX-330, at the recently concluded Society for Immunotherapy of Cancers (SITC) 39th Annual Meeting...
Clinical Study

Advancements in Cancer Treatment: Werewolf Therapeutics Showcases Promising Results wit...

Published Sat, Jun 1 2024 1:00 PM UTC

In the constant battle against cancer, new advancements in treatment options bring hope to patients and healthcare professionals alike. Werewolf Therapeutics, a biopharmaceutical company focused on developing innovative therapies for cancer and immune-mediated diseases, has been at the forefront of groundbreaking research and clinical trials. In this article, we will delve i...
Clinical Study

'Werewolf Therapeutics Unveils Groundbreaking Therapeutic Data: Pioneering New Frontiers in Cancer and Immune-Mediated Diseases'

Published Thu, May 23 2024 9:00 PM UTC

Werewolf Therapeutics, a leader in innovative biotherapeutic developments, is poised to present the latest clinical trial data of its groundbreaking candidate WTX-124 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The updated results from their ongoing Phase 1/1b clinical trial will highlight WTX-124 s impressive tolerability and significant clinica...
Werewolf Therapeutics Inc

Werewolf Therapeutics Inc. Reports -83.378% Drop in Top-Line Revenue for Q1 2024 Earnings Season

Werewolf Therapeutics Inc has recently reported disappointing financial results for the first quarter of 2024, with a significant decline in revenue and an increase in net loss per share compared to the same period last year. The company's revenue dropped by -83.378% to $0.74 million, while the net loss per share swelled to $-0.39, from $-0.28 in the prior reporting period.
The net shortfall for the first quarter of 2024 was reported at $-16.193 million, which is higher than the $-11.982 million loss recorded a year ago. Despite these challenging financial results, Werewolf Therapeutics Inc remains focused on advancing its clinical trials, with an upcoming update on its ongoing monotherapy and combination Phase 1/1b trial of WTX-124 in advanced or metastatic solid tumors scheduled to be presented at ASCO.
Clinical Study

Unleashing the Potential of IL-10 INDUKINE Molecules: Werewolf Therapeutics' PREDATOR Platform Boosts Inflammatory Bowel Disease Therapy

Published Tue, Apr 23 2024 12:01 PM UTC

In a groundbreaking presentation at the AAI Annual Meeting, Werewolf Therapeutics unveiled their pioneering research, highlighting the immense potential of IL-10 INDUKINE molecules as a promising therapy for the treatment of inflammatory bowel disease (IBD). Drawing upon the transformative capabilities of their revolutionary PREDATOR platform, the scientific community witnes...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com